Portola prices biotech IPO; Quintiles investment spinoff nabs $80M;

 @FierceBiotech: NGM raises $13M for cardio/metabolic R&D work. Item | Follow @FierceBiotech

 @JohnCFierce: Astellas, VCs stake virtual biotech spinout with $15M and a PhII program. Release | Follow @JohnCFierce

 @RyanMFierce: Pfizer opts to keep running Accelrys software in its labs. Article | Follow @RyanMFierce

> Portola Pharmaceuticals has set a range of $13 to $16 a share for the 6.9 million shares it plans to sell in a $100 million IPO. Report

> The Seattle-based Accelerator Corp., which finances and launches biotech companies, has plans to open up a second location in New York. Story

> Quintiles spinoff NovaQuest Capital has raised an additional $80 million from investors. The finance group invests in late-stage and commercial assets. Report

> GW Pharma has won approval for Sativex in Italy. Story

> Sanofi Canada officially opened a new headquarters in Laval, Quebec, where the company has operated since 1968. Article

Medical Device News

 @FierceMedDev: Hologic slashes outlook as losses widen. Report | Follow @FierceMedDev

 @MarkHFierce: Dx test maker Quidel now owns BioHelix, for $10M, plus milestone payments. Item | Follow @MarkHFierce

 @DamianFierce: Medtronic won FDA approval for two new cardiac devices. Story | Follow @DamianFierce

> Mindray soars in Q1 with 21% Dx growth. Report

> Mass General repurposes cancer Dx tool for multiple use. DxExtra

Pharma News

 @FiercePharma: Lilly salesforce cuts to be deeper than expected, Indy Biz Journal says: 1,624 jobs, or 40%, not 30%. Report | Follow @FiercePharma

 @EricPFierce: Eli Lilly's CEO John C. Lechleiter will have surgery and be out for some weeks. Release | Follow @EricPFierce

> Don't confuse Kadcyla with Herceptin, FDA says. More

> Lilly CEO set for surgery on dilated aorta; CFO steps up temporarily. Article

> DEA finally acts on Belviq, clearing Arena for diet drug's launch. Article

Pharma Manufacturing News

> Pfizer sells Viagra online to take away play by counterfeiters. Item

> Novo investing $67M in Denmark plant. Article

> J&J dealing with OTC manufacturing issues on 3 continents. Story

> Sagent buys full control of China plant. News

Biotech Research News

 @EmilyMFierce: New molecule could be potential therapy for muscular dystrophy. More | Follow @EmilyMFierce

> Inhibiting a protein could provide new avenue for antidepressant drug development. Report

> Genetic 'switch' could halt aggressive cancer growth. More

> Scientists create more accurate animal model of Type 2 diabetes. Story

> Mayo Clinic develops drug that stops growth of kidney cancer. Article

And Finally… A new survey finds that the top 25 pharma companies in India spend an average of only 6% to 7% of total sales on R&D. Story

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.